Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Emine Sahin
  • Julia Münzker
  • Michael Grusch
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7169-9



Follistatin is a secreted protein that contains three conserved follistatin domains (FSDs) and binds several members of the transforming growth factor beta (TGF-β) family including activins, myostatin, and bone morphogenetic proteins (BMPs). Binding to follistatin abrogates signaling activity of these proteins. The name follistatin is derived from its ability to block activin-induced secretion of follicle-stimulating hormone (FSH) from the pituitary. Follistatin-like (FTSL) proteins contain at least one FSD and have heterogeneous, hitherto only partly characterized, functions.


Follistatin Structure

Secreted follistatin exists in three main forms consisting of 288, 303, and 315 amino acids. The FST...


Chronic Lymphocytic Leukemia Amino Acid Form Activin Signal Nonalcoholic Liver Disease Follistatin Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Aoki F, Kojima I (2007) Therapeutic potential of follistatin to promote tissue regeneration and prevent tissue fibrosis. Endocr J 54:849–854CrossRefPubMedGoogle Scholar
  2. Hedger MP, Winnall WR, Phillips DJ, de Kretser DM (2011) The regulation and functions of activin and follistatin in inflammation and immunity. Vitam Horm 85:255–297CrossRefPubMedGoogle Scholar
  3. Kreidl E, Ozturk D, Metzner T, Berger W, Grusch M (2009) Activins and follistatins: emerging roles in liver physiology and cancer. World J Hepatol 1:17–27CrossRefPubMedPubMedCentralGoogle Scholar
  4. Phillips DJ, de Kretser DM (1998) Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 19:287–322CrossRefPubMedGoogle Scholar
  5. Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schottler A, von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE, Taylor MD, Lichter P, Pfister SM (2011) FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 29:3852–3861CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Institute for Physiology, Center for Physiology and PharmacologyMedical University of ViennaViennaAustria
  2. 2.Division of Endocrinology and Diabetology, Department of Internal MedicineMedical University of GrazGrazAustria
  3. 3.Institute of Cancer Research, Department of Medicine IMedical University of ViennaViennaAustria